USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
OSTEOGENEX, INC
Address:
PO Box 3132
Kansas city, KS 66103-
Phone:
N/A
URL:
N/A
EIN:
103058296
DUNS:
167266555
Number of Employees:
N/A
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $608,980.00 2
SBIR Phase II $994,943.00 1

Award List:

Therapeutics for increasing Bone Density and Quality

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$133,904.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Osteoporosis affects 55% of Americans over the age of 50, and incurs a medical cost of $47 million a day. It is caused by a disruption in the fine equilibrium between bone resorption and bone deposition. Currently, the most successful pharmaceutical drugs for… More

Anabolic Therapeutics for Increasing Bone Denisty and Quality

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$994,943.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): OsteoGeneX is developing a therapeutic directed against the new bone target Sclerostin (SOST) for the treatment of osteoporosis and related bone disorders. Through genomic approaches Sclerostin was identified as a mast er regulator of bone mass affecting men and… More

Oral delivered bone building therapy for osteoporosis

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$475,076.00
Agency:
HHS
Principal Investigator:
Debra L. Ellies – 913-945-6763
Abstract:
DESCRIPTION (provided by applicant): The osteoporosis market is still in demand for new therapeutics due to the lack of safe orally available bone building drugs. Currently, parathyroid hormone (PTH; FORTEOTM) and its analogs are the only bone building therapies available yet they capture only 8% of… More